Терапевтический архив (Jul 2020)

Nephrotoxicity of anti-angiogenesis drugs

  • Katerina S. Grechukhina,
  • Natalia V. Chebotareva,
  • Tatyana N. Krasnova

DOI
https://doi.org/10.26442/00403660.2020.06.000672
Journal volume & issue
Vol. 92, no. 6
pp. 93 – 98

Abstract

Read online

Neoangiogenesis is a basic factor for most physiological as well as pathological processes i.e. tumor metastases. The most important is vascular endothelium growth factor (VEGF) and its receptors (VEGFR1/2) in angiogenesis processes. Nowadays antiangiogenic agents (which inhibit VEGF like bevacizumab neither VEGFR2 like ramucirumab) are widely used in very different chemotherapeutic regimens in clinical oncology. The signalling pathway VEGF-VEGFR plays a crucial role in supporting of adequate kidney function. Appearance of antiangiogenic drugs led to adverse nephrotoxic effects: arterial hypertension, proteinuria, rarely nephrotic syndrome, and kidney dysfunction. Various hystological variants of nephropathy are described, however, in most cases, signs of thrombotic microangiopathy of the renal vessels are noted. This literature review discusses mechanisms, clinical and morphological aspects of nephropathy associated with antiangiogenic drugs.

Keywords